Hyperphosphatemia News and Research

RSS
FDA grants marketing approval for Elitek

FDA grants marketing approval for Elitek

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Program for kidney disease patients effective for reducing serum phosphorus levels

Program for kidney disease patients effective for reducing serum phosphorus levels

Phosphorus binders help dialysis patients

Phosphorus binders help dialysis patients

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Forsenol reduces tablet burden on end stage renal disease patients with hyperphospatemia

Forsenol reduces tablet burden on end stage renal disease patients with hyperphospatemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.